SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Surrozen, Inc./DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.84+0.40 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $551.80M
- P/E (TTM)
- –
- Dividend yield
- –
Surrozen, Inc./DE revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration and license revenue [Member] | $5.00M | $5.00M | $0 | $0 | $0 | $0 | $0 | $10.00M | 100.0% | – |
| Research service revenue [Member] | $0 | $0 | $528.00K | $983.00K | $983.00K | $983.00K | $655.00K | $0 | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Surrozen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.